Results 111 to 120 of about 526 (152)
, 2020 Schweitzer, Paula K,; Rosenberg, Russell,; Zammit, Gary K,; Gotfried, Mark,; Chen, Dan,; Carter, Lawrence P,; Wang, Hao,; Lu, Yuan,; Black, Jed,; Malhotra, Atul,; Strohl, Kingman P,; Blackman, Adam,; George, Charles,; Shapiro, Colin,; Shapiro, Colin,; Benes, Heike,; Fietze, Ingo,; Mayer, Geert,; Young, Peter,; Lammers, Gert Jan,; Ahmed, Mansoor,; Ajayi, Akinyemi,; Andry, James,; Artal, Roy,; Bastani, Bijan,; Bogan, Richard,; Corser, Bruce,; Drake, Christopher,; Emsellem, Helene,; Erman, Milton,; Feldman, Neil,; Foldvary, Nancy,; Gotfried, Mark,; Hudson, John,; Krahn, Lois,; Lorch, Daniel,; Malhotra, Atul,; Maynard, James,; Mignot, Emmanuel,; Neeb, Michael,; Ojile, Joseph,; Perkins, Alvin Thomas,; Rosenberg, Russell,; Roy, Asim,; Sahota, Pradeep,; Sangal, R Bart,; Schreiber, Andrew,; Schweitzer, Paula,; Steele, Ralph,; Stern, Thomas,; Stern, Thomas,; Stolz, Sarah,; Strohl, Kingman,; Swick, Todd,; Swick, Todd J,; Thein, Stephen G,; Thomas, Robert,; Thorpy, Michael,; Weaver, Terri,; Wilks, Kerri,; Winslow, David
core
Solriamfetol in excessive daytime sleepiness: a profile of its use
Drugs & Therapy Perspectives, 2020 Oral solriamfetol (Sunosi™), a selective dopamine and norepinephrine reuptake inhibitor, is approved to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA) in the USA and EU.
Emma D. Deeks, Young-A Heo
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
False positive urine amphetamine immunoassay due to solriamfetol
Sleep Medicine, 2023Solriamfetol is a schedule IV-controlled substance used to treat excessive daytime sleepiness resulting from narcolepsy or obstructive sleep apnea. We present a patient prescribed solriamfetol who tested positive for amphetamines on a routine urinary toxicology screen despite patient denial of illicit drug use, raising the possibility of a false ...
Dennis Auckley +2 more
exaly +3 more sources
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea
Annals of Pharmacotherapy, 2020Objective: The purpose of this article is to review the available clinical trial data that led to the Food and Drug Administration (FDA) approval of solriamfetol as well as its role in clinical practice. Data Sources: A MEDLINE/PubMed ...
Jason Powell +1 more
exaly +3 more sources
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy
Expert Review of Clinical Pharmacology, 2019Introduction: Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it. There is currently no cure for narcolepsy, and hence there is a great need for new treatment options. Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects.
Junyi Yang
exaly +3 more sources
Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea
Expert Review of Respiratory Medicine, 2018Introduction: Obstructive sleep apnea (OSA) is highly prevalent and constitutes a major health hazard. Current pharmacotherapy is ineffective in correcting sleep-disordered breathing and is used adjunctively to address residual sleepiness. A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class ...
exaly +3 more sources
CNS Drugs, 2023 Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake inhibitor approved in the EU and the USA for improving wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA).
Sheridan M. Hoy (4897468)
openaire +3 more sources
Sleep Medicine, 2022 International audienceObjectives: This analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (Sunosi™) 37.5 (OSA only), 75, 150, or 300 mg/d.Methods: In two 12-week, randomized,
Patricia Chandler +2 more
exaly +3 more sources